

1 **Evaluation of Six Commercial and Non-Commercial Colistin Resistance Diagnostics**

2 Tumisho Mmatumelo Seipei Leshaba<sup>a</sup>, Masego Mmatli<sup>a</sup>, Lebogang Skosana<sup>ab</sup>, Nontombi

3 Marylucy Mbelle<sup>a</sup>, John Osei Sekyere<sup>#acd</sup>

4 <sup>a</sup> Department of Medical Microbiology, School of Medicine, University of Pretoria, South  
5 Africa.

6 <sup>b</sup> Department of Medical Microbiology, Tshwane Academic Division, National Health  
7 Laboratory Service, Pretoria, South Africa

8 <sup>c</sup> Department of Dermatology, School of Medicine, University of Pretoria, South Africa

9 <sup>d</sup> Institute of Biomarker Research, Medical Diagnostic Laboratories, Genesis Biotechnology  
10 Group, Hamilton, NJ, United States

11 #Address correspondence to Dr. John Osei Sekyere, Department of Dermatology, School of  
12 Medicine, University of Pretoria, 0084 Pretoria, South Africa: [j.oseisekyere@up.ac.za](mailto:j.oseisekyere@up.ac.za);  
13 [jod14139@gmail.com](mailto:jod14139@gmail.com)

14

15 **Running head:** *Evaluation of colistin resistance diagnostic tests.*

16 **Tweet:** *“Vitek 2, Sensititre, and ComASP colistin proved superior colistin MIC tests when  
17 evaluated among six tests. The Rapid NP test was comparatively efficient with a shorter  
18 turnaround time, albeit with higher very major errors.”*

19

20

21

22

23 **Abstract**

24 **Background.** Resistance to colistin, a last-reserve antibiotic used for treating drug-resistant  
25 infections, is increasing globally. This study evaluated six diagnostic tests designed to detect  
26 colistin-resistant pathogens.

27 **Methods.** PCR and broth microdilution assays (BMD) were used to respectively characterize  
28 the molecular mechanisms and phenotypic colistin resistance of 142 Gram-negative bacterial  
29 isolates and controls. The sensitivity, specificity, positive- and negative-predictive values,  
30 major (ME) and very major errors (VME), categorical and essential agreements (EA) of  
31 ComASP Colistin, CHROMagar COL-APSE, Rapid NP Test, Sensititre, MicroScan, and  
32 Vitek 2 were determined with these isolates; the BMD was used as gold standard.

33 **Results.** The Vitek 2, Sensititre, and ComASP tests were more efficient, albeit with  
34 concerning ME and VMEs and low EAs. Sensititre was 100% specific with 0% ME and  
35 3.61% VME; Vitek 2 had the least VME (1.25% and 0%) and a low EA (57.50%). ComASP  
36 had an EA of 75.35%. MicroScan was highly sensitive (96.55%) but less specific (87.50%),  
37 with very below-acceptable EAs (48.11%). The CHROMagar COL-APSE efficiently  
38 identified the species with their unique colours but was the least specific (67.80%), with the  
39 highest ME (32.20%) and high VME (7.23%). The Rapid NP test had the highest VME  
40 (7.84%), producing results within 4 hours with 92.16% sensitivity and 96.08% specificity.

41 **Conclusion:** Vitek 2, MicroScan, ComASP colistin, and Sensititre are good for determining  
42 colistin resistance; the latter two tests are recommendable for low-resourced laboratories. The  
43 in-house Rapid NP test has short turnaround time with high efficiency for initial resistance  
44 screening.

45 **Keywords:** colistin resistance; tests; assays; polymyxins; *Enterobacterales*.

46

## 47 **Introduction**

48 Increasing use of carbapenems to treat multidrug-resistant bacterial infections invariably led  
49 to the adoption of colistin as a last-reserve antibiotic to counter infections that are resistant to  
50 carbapenems [1–3]. Hence, bacteria that are resistant to colistin are increasingly being  
51 reported worldwide [4–6]. Resistance to colistin is mediated by several molecular  
52 mechanisms, including the mobile colistin resistance (*mcr*) gene, mutations in the PmrAB and  
53 PhoPQ two-component systems, and mutation(s) in the MgrB regulator in *Klebsiella*  
54 *pneumoniae* [1,2,4,7]. These molecular mechanisms, alongside efflux hyperexpression and  
55 porin downregulation, and/or Ecr transmembrane protein mediate phenotype colistin  
56 (polymyxin) resistance and heteroresistance [1,8,9].

57

58 To help clinicians easily detect and monitor colistin-resistant infections, several diagnostic  
59 tests and assays, both commercial and non-commercial, have been designed and developed  
60 [3,10–12]. Some of these tests (such as the BMD, ComASP™ Colistin, MicroScan, Sensititre  
61 and Vitek) are mainly MIC (minimum-inhibitory concentration)-based, measuring only the  
62 MICs of the isolates while others are non-MIC—based, purely providing a binary result of  
63 resistant or sensitive (such as the CHROMagar COL-APSE, and Rapid NP test) [10–12]. The  
64 Rapid NP test was designed to only detect colistin resistance in *Enterobacteriales* and is  
65 therefore not useful for all Gram-negative bacteria [10,13]. As a follow-up to previous  
66 research [11], we used 142 Gram-negative isolates and controls to evaluate the performance  
67 of six colistin resistance diagnostic tests: ComASP Colistin, CHROMagar COL-APSE, Rapid  
68 NP test, Sensititre, Vitek 2, and the MicroScan. The BMD remains the gold standard for  
69 testing colistin MICs and resistance in bacteria [10]; hence it was used as the reference  
70 standard in these evaluation studies.

71

## 72 **METHODS**

### 73 **Demographics and source of clinical specimen and isolates**

74 The evaluation study was conducted on a collection of 134 Gram-negative clinical bacterial  
75 (GNB) isolates including *Enterobacterales* (n=103), *Acinetobacter baumannii* (n=21) and  
76 *Pseudomonas aeruginosa* (n=10) that were collected from the National Health Laboratory  
77 Services, Tshwane Academic Division. Eight control strains were also included to make up to  
78 142: *Escherichia coli* MC1, *E. coli* MC2, *E. coli* MC3, *Salmonella* group D MC4, *Salmonella*  
79 group D MC5, *E. coli* (mcr-1) EMRC, *E. coli* ATCC 25922 (EATCC), *P. aeruginosa* ATCC  
80 27853 (PATCC). Species identification was performed as part of routine laboratory testing  
81 using Vitek® 2 automated system (Biomerieux, France) (Table S1). Demographic data such  
82 as sex, age and sample source were retrieved from the NHLS TrakCare system (Table S1).  
83 The National Food Institute, Technical University of Denmark provided five *mcr*-gene control  
84 strains (four *E. coli* with *mcr-1*, *mcr-2*, *mcr-3* and *mcr-4*, as well as one *Salmonella* spp. with  
85 *mcr-5*) for this study. Antimicrobial susceptibility testing also included one *Escherichia coli*  
86 ATCC 25922 and one *P. aeruginosa* ATCC 27853.

87 The labels of the isolates used in this article are known to only the researchers as the original  
88 labels were de-identified to maintain the patients anonymity.

89

90 **Broth Microdilution.** The reference minimum inhibitory concentration (MIC) of each isolate  
91 was determined by manual broth microdilution (BMD) according to ISO standard 20776-1  
92 [14]. Colistin sulfate powder (Glentham Life Sciences, England) was diluted in cation-  
93 adjusted Mueller Hinton broth (CAMHB) in untreated 96-well microtiter polystyrene plates  
94 (Eppendorf, Germany). Dilutions to the MIC range 128-0.25 µg/mL were established.  
95 Colistin sensitivity results were interpreted according EUCAST breakpoints (susceptible  
96  $\leq 2$  mg/L; resistant  $> 2$  mg/L). (<https://www.nature.com/articles/s41598-020-63267-2>).

97 **Detection of *mcr*-genes.** All isolates were screened for the presence of *mcr*-1, *mcr*-2, *mcr*-3,  
98 *mcr*-4 and *mcr*-5 genes using PCR. The multiplex PCR method previously described by  
99 Rebelo *et al.* was used for the screening of *mcr*-genes [15]. The *mcr*-gene control strains  
100 supplied by the kind courtesy of Professor Rene S. Hendriksen of the National Food Institute,  
101 Technical University of Denmark, were used as positive controls.

102 **Vitek 2 system.** Besides species identification, the Vitek was also used to determine the MICs  
103 of the isolates, using the manufacturer's protocols.

104 **MicroScan.** The MicroScan walkaway system (Beckman Coulter, South Africa) was used to  
105 determine the sensitivity of the species to colistin using the manufacturer's protocol. Briefly,  
106 an overnight culture grown on blood agar was immediately standardized using the the prompt  
107 inoculation system provided in the reagent packaging for MicroScan AST (antimicrobial  
108 sensitivity testing) and identification (ID) testing. The suspension was placed into the N66  
109 and processed overnight in the MicroScan machine.

110 **ComASP™ Colistin.** ComASP™ Colistin by Liofilchem (Roseto degli Abruzzi, Italy) is a  
111 compact panel containing freeze-dried colistin which when diluted should result in two-fold  
112 dilutions ranging from 0.25-16 µg/mL [11,16]. The non-automated BMD-based assay allows  
113 for four samples to be tested on a single test. The manufacturer's instructions were followed  
114 to perform the ComASP™ Colistin test. A 0.5 McFarland suspension of the isolates was  
115 prepared in a solution of 250 mL saline and then diluted to 1:20 in saline (Gibco, Thermo  
116 Fisher Scientific, USA) to obtain solution A. Solution A (0.4 mL) was added to a tube  
117 containing 3.6mL Mueller-Hinton broth provided by the ComASP™ Colistin to obtain  
118 solution B. One hundred microliters of solution B were dispensed into each well and the  
119 panels were incubated (Vacutec, US) at 36±2°C for 16 to 20 hours in ambient air. Results  
120 were read by visually analysing the plates for turbidity.

121 **ChromAgar Col-APSE.** Fresh 24-hour culture of each isolate was dissolved in saline and  
122 adjusted to 0.5 McFarland's standard. This suspension was spread on the ChromAgar Col-  
123 APSE plate and incubated for 18 - 24 hours. The manufacturer's protocol was used  
124 throughout this test (<https://www.nature.com/articles/s41598-020-63267-2>).

125 **Sensititre™.** Sensititre™ (Thermo Fisher Scientific, USA) "FROL" colistin-customised  
126 plates were used in this study. A 0.5 McFarland standard in saline was prepared for each  
127 isolate (Gibco, Thermo Fisher Scientific, USA). Ten microlitres of the 0.5 McFarland  
128 suspension was transferred into an 11 mL tube containing CAMHB with TES buffer for all  
129 non-intrinsic *Enterobacteriales*, *A. baumannii* and *P. aeruginosa* isolates. However, for  
130 *Proteus* species, *Providencia* spp. and *Morganella morganii* 1 µL was transferred into the 11  
131 mL CAMHB tube. Each Sensititre™ plate constitutes of eight rows with 12 wells, each row  
132 allows for the testing of one isolate at different concentrations of colistin. Wells 1-11 contain  
133 dehydrated colistin at concentrations of 0.12-128 µg/mL, respectively. Well 12 represents a  
134 positive control and therefore does not contain colistin. Each well was inoculated with 50 µL  
135 of the bacterial broth suspension using a manual pipette. Each plate was then covered with an  
136 adhesive seal and incubated (Vacutec, US) at ± 35°C in an aerobic environment. Results were  
137 read by visually analysing the plates for turbidity.

#### 138 **In-house Rapid Polymyxin NP test.**

139 Rapid Polymyxin NP test is based on the detection of glucose metabolism related to  
140 *Enterobacteriales* growth in the presence of a defined concentration of colistin [17]. The  
141 formation of acid metabolites is shown by a colour change of a pH indicator (red phenol) in  
142 less than 4 hours [17,18]. The rapid NP test was performed as described by Nordmann *et al*,  
143 2016 [6,19–21]. To prepare the NP test solution, a 6.25g of CAMHB broth powder and  
144 0.0125g of phenol red powder was added to 225 mL of distilled water. The pH of the solution  
145 was then adjusted to 6.7 by adding 1-N HCL in drops after which the solution was

146 autoclaved. A 25 mL of 10% anhydrous D-glucose solution that had been sterilised by  
147 filtration was added to the autoclaved CAMHB solution. Colistin stock solution (1280  
148  $\mu\text{g/mL}$ ) was diluted to 200  $\mu\text{g/mL}$  working solution by adding 1 mL of the stock solution to  
149 5.4 mL CAMHB. To make colistin-NP test solution, 100  $\mu\text{L}$  of the colistin working solution  
150 (200  $\mu\text{g/mL}$ ) was added to 3900  $\mu\text{L}$  NP test solution to get a final concentration of 5  $\mu\text{g/mL}$ .  
151 The Rapid Polymyxin NP test was carried out in 96 well polystyrene plates (Eppendorf,  
152 Germany). A 150  $\mu\text{L}$  of NP test solution alone without colistin was added to wells 1, 3, 5, 7,  
153 9 and 11 of each row (A-H) of the 96-well microtiter plates. Wells 2, 4, 6, 8, 10 and 12  
154 contained 150  $\mu\text{L}$  of colistin-NP test solution (5  $\mu\text{g/mL}$ ). *Proteus mirabilis* isolate from our  
155 collection was used as a resistant control and *Escherichia coli* ATCC 25922 was used as a  
156 susceptible control.

157 A 3.5 McFarland standard was prepared for each test isolates with sterile 0.85% NaCl  
158 solution and used within 15 of preparation. Each *Enterobacterales* isolate was inoculated (50  
159  $\mu\text{L}$ ) in parallel into the two wells, one without colistin and one with colistin. Wells H7-8 were  
160 inoculated 50  $\mu\text{L}$  *P. mirabilis* and wells H9-10 were inoculated with 50  $\mu\text{L}$  *E. coli* ATCC  
161 25922. Wells H11-12 were inoculated with 50  $\mu\text{L}$  of 0.85% NaCl solution. The microtiter  
162 plates were incubated for 3 h at  $35 \pm 2$ , after 3 h of incubation, the isolates were checked for  
163 change in colour every 15 minutes until 4 h of incubation. The results were read visually  
164 where a change in colour of phenol red (orange to bright yellow) indicated growth.

### 165 **Data analysis**

166 All six antimicrobial susceptibility testing methods were compared to the ISO standard  
167 20776-1 BMD. Colistin MIC results were interpreted using EUCAST's breakpoints  
168 (susceptible,  $\leq 2$   $\mu\text{g/mL}$ ; resistant,  $>2$   $\mu\text{g/mL}$ ). For each test, the false positives, false  
169 negatives, true positives, and true negatives were determined and used for downstream  
170 determination of the other performance indices (Table S1). We calculated the rates of

171 essential agreement (EA), categorical agreement (CA), very major error (VME), and major  
172 error (ME) using already described methods [11]. Categorical agreement was defined as an  
173 agreement in the classification of susceptible or resistant between the evaluated test and the  
174 reference BMD. Essential agreement was defined as an MIC value within a 2-fold (one  
175 doubling) dilution of the BMD result. A very major error occurred when the tested method  
176 interpretation of an isolate was susceptible while the BMD interpretation was resistant for the  
177 same isolate. A major error occurred when the investigated method's interpretation was  
178 resistant, and the BMD interpretation was susceptible for the same isolate. The sensitivity and  
179 specificity of each test were calculated as previously described [11].

180

181 GraphPad Prism 10 was used to calculate the odds ratio and Fisher's exact test to determine  
182 the significance of each test's results against the BMD.

183

## 184 **RESULTS**

185 **Reference BMD.** Reference MICs of all 142 isolates were determined by standard broth  
186 microdilution (BMD), either in this study or as standard protocol by the National Health  
187 Laboratory Services Tshwane Academic Division. One *A. baumannii*, 51 *Enterobacterales*  
188 and seven *P. aeruginosa* isolates were colistin-susceptible with BMD, including one *E. coli*  
189 ATCC 25922 and a *P. aeruginosa* ATCC 27853 (Table 1). The colistin-resistant isolates by  
190 BMD include 59 *Enterobacterales*, 20 *A. baumannii* and four *P. aeruginosa*. Apart from the  
191 five *mcr* control strains, only two isolates, BB2 and EMRC, had *mcr-1* genes (Table 1).  
192 Isolate BB2 is an *A. baumannii* with a MIC of 32 µg/mL, while isolate EMRC is an *E. coli*  
193 with a MIC of 4 µg/mL. All eight intrinsically colistin-resistant *Enterobacterales* (*Proteus*  
194 *mirabilis*, *Serratia marcescens*, *Morganella morganii*, *Proteus vulgaris*, *Providencia stuartii*,  
195 and *Ralstonia/Burkholderia pickettii*) had MICs  $\geq$  128 µg/mL (Table 1).



196

197 **Commercial BMD methods.** All 142 isolates were tested on ComASP™ Colistin and  
198 Sensititre™. ComASP™ Colistin and Sensititre™ both had a satisfactory categorical  
199 agreement of 96.48% and 97.18%, respectively. However, ComASP™ Colistin falsely  
200 detected one *K. pneumoniae* (1µg/mL) and one *P. aeruginosa* (1µg/mL) as colistin-  
201 susceptible isolates, resulting in 3.40% MEs. Sensititre™ accurately identified all colistin-  
202 susceptible isolates. However, it failed to identify three colistin-resistant isolates, therefore  
203 resulting in no MEs and 3.61% VMEs. Most isolates that were not detected by Sensititre™  
204 and ComASP™ Colistin had MICs close to the breakpoints (4-8µg/mL). Only one isolate that  
205 was not detected by Sensititre™ had an MIC >8 µg/mL i.e., a *K. pneumoniae* with an MIC of  
206 32µg/mL. ComASP™ Colistin had an overall sensitivity and specificity of 96.39% and  
207 96.61%, respectively, whereas Sensititre™ had 96.39% and 100% (Table 2).

208 Notably, ComASP™ fared better with *Enterobacterales* than with all Gram-negative bacteria  
209 as its sensitivity (98.31%), specificity (98.04%), and CA (98.18%) increased while its ME  
210 (1.96%) and VMEs (1.72%) reduced (Table 2): the EA, however, increased from 69.09% in  
211 *Enterobacterales* to 75.35% in GNB. Sensititre's *Enterobacterales* results were comparably  
212 similar to that of its GNB results (Table 2).

213 Vitek MIC results were obtained for 120 GNB and 94 *Enterobacterales*. Vitek had the highest  
214 sensitivity and the second or third highest specificity among GNB and *Enterobacterales*,  
215 respectively, for all the tests. It had the highest CA, the second lowest EA (after MicroScan),  
216 and one of the lowest VME among the six tests (Table 2). The Microscan was equally highly  
217 sensitive but less specific, with the lowest EA (46.11% and 46.91%) among all the MIC-  
218 based tests. Its sensitivity was 96.55% and 100% for GNB and *Enterobacterales* respectively.  
219 The MicroScan's MEs with both GNB and *Enterobacterales* (12.50% and 12.20%) were only

220 second to that of the CHROMAgar Col-APSE (Table 2) and its VMEs were 3.45% (GNB)  
221 and 0% (*Enterobacterales*).

222 **CHROMAgar Col-APSE.** A total of 96/142 isolates grew on CHROMAgar Col-APSE: BMD  
223 identified 19 of them as colistin susceptible, resulting in 32.20% ME and 67.80% specificity.  
224 Most of the MEs (14/19) were due to *Klebsiella* spp. The chromogenic media detected most  
225 colistin-resistant isolates (77/83), but it also produced a high percentage of VMEs (7.23%),  
226 resulting in a sensitivity of 92.77%. Among *Enterobacterales* alone, CHROMAgar was less  
227 sensitive (91.53%) and more specific (68.63%), with fewer MEs (31.37%) and CA (80.91%)  
228 than in GNB (Table 2).

229 Differentiation of the isolated bacteria by the morphological appearance of their colonies was  
230 as described by the manufacturer [22]. Metallic blue (*Klebsiella*, *Enterobacter* and *Serratia*  
231 spp.), cream white (*Acinetobacter*, *Salmonella* and *Pseudomonas* spp.), pink-red (*E. coli*)  
232 colonies were observed (Fig. 1) [22]. Furthermore, *E. coli* could be distinguished as  
233 fermenting (blue with pink borders) and non-fermenting strains (pink). Swarming was  
234 observed on the *P. mirabilis*-inoculated plate because the plate was not supplemented with p-  
235 nitrophenyl glycerol as recommended by Abdul Momin *et al* (2017) (Figure 1) [22].

236 **In-house Rapid NP Test.** Only 102/142 of the isolates that were *Enterobacterales* were  
237 included in this test. This included 51 colistin-susceptible and 51 non-intrinsically colistin-  
238 resistant *Enterobacterales* isolates. The overall sensitivity and specificity of the in-house  
239 Rapid polymyxin NP test was 92.16% and 96.08% respectively. Colistin-resistant isolates  
240 that were not detected include one *Salmonella* spp., two *K. pneumoniae* and one *E. coli*, with  
241 MICs ranging from 4 – 128 µg/mL. Two of the false-resistant isolates, also grew on  
242 CHROMAgar Col-APSE (Table S1). In this study, most results were positive within two  
243 hours of incubation. Six isolates, however, were not detectable after three hours of incubation

244 but were positive after four hours. Amongst the slow-growing isolates were four *Salmonella*  
245 spp., one *E. coli*, and one *E. cloacae*.

246

## 247 **DISCUSSION**

248 The proliferation of colistin resistance among GNB has necessitated the development of  
249 better diagnostics to quickly and efficiently detect colistin-resistant organisms to control their  
250 spread [1,2,4,10,11]. This study evaluated six antimicrobial susceptibility tests that were  
251 developed to detect colistin-resistance with efficiency. Broth microdilution is currently the  
252 golden standard for colistin susceptibility testing; however, it is considered tedious and  
253 difficult [10]. Vitek 2, ComASP™ Colistin, and MicroScan had the best detection  
254 (sensitivity) of colistin-resistant isolates (Table 2). When compared with Sensititre™,  
255 CHROMagar Col-APSE, the Rapid Polymyxin NP test, ComASP™ Colistin, and MicroScan,  
256 Vitek 2 produced the least VMEs at 1.25% and 0% for GNB and *Enterobacterales*,  
257 respectively. This was followed by the MicroScan and ComASP, with VMEs of 3.45% vs  
258 3.57% and 0% vs 1.96% respectively for all isolates and *Enterobacterales* (Table 2).

259

260 In essence, the Vitek 2, which is common in many well-resourced routine diagnostic  
261 microbiology laboratories, is very efficient in detecting colistin resistance albeit its low EA  
262 should be considered when using MICs from Vitek 2. Moreover, its initial cost, long  
263 turnaround time, and skill required to operate it make it inaccessible to low-resourced  
264 laboratories. Although the MicroScan is also highly sensitive with low VMEs (particularly  
265 among *Enterobacterales*), its lower specificity and EA, 18 – 24-hour turnaround time,  
266 operating skill required, and initial cost are also major disadvantages for low-resourced  
267 laboratories [10–12]. The ComASP and Sensititre are two affordable commercial kits that can  
268 be adopted in low-resourced laboratories for colistin resistance diagnosis. The Sensititre had

269 100% specificity and 72.54% vrs 71.82% EA for both GNB and *Enterobacteriales*, which  
270 were the best (with ComASP) among all the six tests. Hence, in terms of cost and required  
271 skill, the Sensititre and ComASP are good alternatives for determining the colistin MICs and  
272 resistance.

273

274 The EA recorded in this study for both commercial BMD methods is below the recommended  
275 EA ( $\geq 90\%$ ) for antimicrobial susceptibility testing systems. The EA did not improve when  
276 analysing *Enterobacteriales* alone for ComASP™ Colistin, MicroScan, and Sensititre™;  
277 Vitek 2, however, had an increase from 57.50% (Gram-negative bacteria) to 59.78%  
278 (*Enterobacteriales*) (Tables 1-2). ComASP™ Colistin tended to decrease or increase the MIC  
279 of a significant number of colistin-susceptible isolates (29/59) by one two-fold dilution (Table  
280 S1). Notwithstanding, this observation did not change the CA between ComASP™ Colistin  
281 and the reference BMD.

282

283 In this study, CHROMagar Col-APSE produced the highest rate of MEs and a high VME  
284 second only to that of the in-house Rapid NP test (Tables 1-2), particularly for *Klebsiella* spp.  
285 Although the specificity recorded in this study and that of Osei Sekyere *et al* (at 66,67%)  
286 agree, two other studies recorded a significantly higher specificity of  $\geq 97\%$  [11,22,23].  
287 These discrepancies could be attributed to the different bacterial inoculum concentrations  
288 used. Ali *et al* demonstrated that when a 0.5 McFarland standard inoculum was used, colistin-  
289 susceptible isolates were able to grow on the media [23], whereas the same isolates were  
290 inhibited when the inoculum was diluted to a density of  $1 \times 10^5$  CFU/mL. Therefore, the high  
291 rate of MEs in this present study could be due to the inoculum used being a 0.5 McFarland  
292 standard ( $1.5 \times 10^8$  CFU).

293

294 The in-house Rapid Polymyxin NP test was expected to have the best performance for  
295 *Enterobacterales*. Even though the test was designed specifically for colistin susceptibility  
296 testing on *Enterobacterales*, its performance was inferior to that of commercial BMD  
297 methods (Tables 1-2). Compared with other studies that have achieved a sensitivity of  $\geq 97\%$ ,  
298 the overall performance of the in-house Rapid Polymyxin in this study ( $\sim 92\%$ ) is slightly  
299 poor [17,18,24]. The CA of all the tests evaluated in this study except for CHROMAgar Col-  
300 APSE, is within the recommended standard ( $\geq 90\%$ ) for antimicrobial susceptibility testing  
301 systems. Nevertheless, except for Vitek 2 for all GNB and MicroScan in only  
302 *Enterobacterales*, all the other evaluated tests had an unacceptable VME rate of  $\geq 1.5\%$ .  
303 Only Sensititre™ had an acceptable rate of MEs when all isolates were considered, but  
304 ComASP™ Colistin's ME improved when only *Enterobacterales* were examined.

305

306 Therefore, for low-resourced laboratories and research institutions, the in-house Rapid NP  
307 test is a better option in terms of turnaround time, cost, and efficiency than the CHROMAgar  
308 COL-APSE, except that the latter has advantages of easy use and species identification  
309 through its chromogenic compounds. In terms of cost and turnaround time, the CHROMAgar  
310 is comparable to the two other commercial MIC tests: Sensititre and ComASP. Nevertheless,  
311 the higher efficiency of the former two and their ability to provide actual MICs make them  
312 recommendable. Yet, CHROMAgar is easier to use than these two MIC tests and the MICs of  
313 ComASP should be used with caution among *Enterobacterales* owing to its 75.35% EA.

314

315 The statistical odd ratio and *p*-values metrics indicate that the tests, specifically the Vitek 2,  
316 Sensititre™, ComASP™ Colistin, MicroScan, and the in-house Rapid NP test, have a  
317 relatively high level of performance in identifying both resistant and sensitive isolates among  
318 GNB. The PPV and NPV suggest that the tests' predictive values are highly reliable. The

319 odds ratio suggests a very strong association between the test results and the resistance being  
320 tested for, indicating that the likelihood of detecting resistant isolates is significantly higher  
321 when they are truly resistant, as compared to when they are not. The extremely low p-value  
322 indicates that this finding is statistically significant, meaning there's a very small chance that  
323 these results could have occurred by random variation alone.

## 324 **CONCLUSION**

325 This study discovered that commercial BMD methods had the best overall performance. In  
326 the absence of resources to purchase the Vitek 2 or the MicroScan, we recommend the  
327 ComASP™ Colistin and Sensititre™ as potential alternative MIC tests for routine colistin  
328 antimicrobial susceptibility testing in clinical laboratories. However, isolates with MICs close  
329 to the breakpoint may be misinterpreted by commercial BMD tests. As the in-house Rapid  
330 NP test had the quickest turnaround time, we recommend it for colistin susceptibility testing  
331 on *Enterobacteriales*, particularly in laboratories with limited resources and labour skill.  
332 Notably, CHROMAgar Col-APSE produced the most errors; with colistin being a last-reserve  
333 antibiotic, minimal error is critical. Hence, the use of CHROMAgar Col-APSE should be  
334 validated further, possibly with lower inoculum. Notably, all the tests were able to detect  
335 colistin resistance in *mcr*-positive strains.

336

337 **Acknowledgements:** We are grateful to the staff of the NHLS-TAD for their support and  
338 assistance in collecting and plating the isolates. We hereby regretfully report the death of our  
339 colleague Professor Nontombi Marylucy Mbelle, who died during the course of this  
340 investigation. This work is dedicated to her memory. We are ever grateful to Professor Rene  
341 S. Hendriksen, Ana Rita Bastos Rebelo, and Troels Ronco of the National Food Institute,  
342 Technical University of Denmark, for their donation of the *mcr-1* to *mcr-5* positive controls.

343 **Funding:** This work was funded by a grant from the National Health Laboratory Service  
344 (NHLS) given to Dr. John Osei Sekyere under grant number GRANT004 94807 and  
345 GRANT004 94808.

346 **Transparency declaration:** The authors declare no conflict of interest.

347 **Author contributions:** TMSL undertook the laboratory investigations, undertook initial  
348 analysis of the data and drafted the manuscript. MM assisted with the laboratory work.  
349 BLS assisted with isolates collection and plating. NMM co-supervised the study. JOS  
350 designed and supervised the study, undertook data analysis, and wrote the manuscript.  
351 All authors reviewed the final version of the manuscript.

352 **Ethical approval:** The study was approved by the Research Ethics Committee, Faculty of  
353 Health Sciences, University of Pretoria, under reference number 550/2020. The study  
354 complied with the ICH-GCP guidelines and the Helsinki declaration.

## 355 **References**


- 356 [1] Mmatli M, Mbelle NM, Maningi NE, Osei Sekyere J. Emerging Transcriptional and Genomic  
357 Mechanisms Mediating Carbapenem and Polymyxin Resistance in Enterobacteriaceae: a Systematic  
358 Review of Current Reports. *MSystems* 2020;5. <https://doi.org/10.1128/mSystems.00783-20>.
- 359 [2] Mmatli M, Mbelle NM, Osei Sekyere J. Global epidemiology, genetic environment, risk factors and  
360 therapeutic prospects of mcr genes: A current and emerging update. *Front Cell Infect Microbiol* 2022;12.  
361 <https://doi.org/10.3389/fcimb.2022.941358>.
- 362 [3] Mmatli M, Leshaba TMS, Skosana LB, Mbelle NM, Osei Sekyere J. Molecular Screening of Clinical  
363 Multidrug-Resistant Gram-Negative Bacteria Shows Endemicity of Carbapenemases, Coexistence of  
364 Multiple Carbapenemases, and Rarity of mcr in South Africa. *Microb Drug Resist* 2022;28:1028–36.  
365 <https://doi.org/10.1089/MDR.2022.0112>.
- 366 [4] Ramaloko WT, Osei Sekyere J. Phylogenomics, epigenomics, virulome and mobilome of Gram-negative  
367 bacteria co-resistant to carbapenems and polymyxins: a One Health systematic review and meta-  
368 analyses. *Environ Microbiol* 2022;24:1518–42. <https://doi.org/10.1111/1462-2920.15930>.
- 369 [5] Lowe M, Shuping L, Perovic O. Carbapenem-resistant Enterobacterales in patients with bacteraemia at  
370 tertiary academic hospitals in South Africa, 2019 - 2020: An update. *South African Med J*  
371 2022;112:545–52. <https://doi.org/10.7196/SAMJ.2022.V112I8.16351>.
- 372 [6] Jayol A, Dubois V, Poirel L, Nordmann P. Rapid Detection of Polymyxin-Resistant Enterobacteriaceae  
373 from Blood Cultures. *J Clin Microbiol* 2016;54:2273–7. <https://doi.org/10.1128/JCM.00918-16>.
- 374 [7] Osei Sekyere J, Reta MA, Fourie PB. Risk factors for, and molecular epidemiology and clinical  
375 outcomes of, carbapenem- and polymyxin-resistant Gram-negative bacterial infections in pregnant  
376 women, infants, and toddlers: a systematic review and meta-analyses. *Ann N Y Acad Sci* 2021:1–18.  
377 <https://doi.org/10.1111/nyas.14650>.



- 378 [8] Halaby T, Kucukkose E, Janssen AB, Rogers MRC, Doorduijn DJ, van der Zanden AGM, et al.  
379 Genomic Characterization of Colistin Heteroresistance in *Klebsiella pneumoniae* during a Nosocomial  
380 Outbreak. *Antimicrob Agents Chemother* 2016;60:6837–43. <https://doi.org/10.1128/AAC.01344-16>.
- 381 [9] Poirel L, Jayol A, Nordmann P. Polymyxins: Antibacterial Activity, Susceptibility Testing, and  
382 Resistance Mechanisms Encoded by Plasmids or Chromosomes. *Clin Microbiol Rev* 2017;30:557–96.  
383 <https://doi.org/10.1128/CMR.00064-16>.
- 384 [10] Leshaba TMS, Mbelle NM, Osei Sekyere J. Current and emerging polymyxin resistance diagnostics: a  
385 systematic review of established and novel detection methods. *J Appl Microbiol* 2021:jam.15184.  
386 <https://doi.org/10.1111/jam.15184>.
- 387 [11] Osei Sekyere J, Sephofane AK, Mbelle NM. Comparative Evaluation of CHROMagar COL-APSE,  
388 MicroScan Walkaway, ComASP Colistin, and Colistin MAC Test in Detecting Colistin-resistant Gram-  
389 Negative Bacteria. *Sci Rep* 2020;10:1–13. <https://doi.org/10.1038/s41598-020-63267-2>.
- 390 [12] Osei Sekyere J. Mcr colistin resistance gene: a systematic review of current diagnostics and detection  
391 methods. *Microbiologyopen* 2019;8:e00682. <https://doi.org/10.1002/mbo3.682>.
- 392 [13] Jayol A, Nordmann P, Lehours P, Poirel L, Dubois V. Comparison of methods for detection of plasmid-  
393 mediated and chromosomally encoded colistin resistance in Enterobacteriaceae. *Clin Microbiol Infect*  
394 2017;pii:S1198-30291–4. <https://doi.org/10.1016/j.cmi.2017.06.002>.
- 395 [14] International Organization for Standardization. Susceptibility testing of infectious agents and evaluation  
396 of performance of antimicrobial susceptibility test devices - Part 1: Broth micro-dilution reference  
397 method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobi. *Biol Eval*  
398 *Med Devices* 2019;19. <https://www.iso.org/obp/ui/#iso:std:iso:20776:-1:ed-2:v2:en> (accessed March 19,  
399 2024).
- 400 [15] Rebelo AR, Bortolaia V, Kjeldgaard JS, Pedersen SK, Leekitcharoenphon P, Hansen IM, et al. Multiplex  
401 PCR for detection of plasmid-mediated colistin resistance determinants, mcr-1, mcr-2, mcr-3, mcr-4 and  
402 mcr-5 for surveillance purposes. *Euro Surveill Bull Eur Sur Les Mal Transm = Eur Commun Dis Bull*  
403 2018;23. <https://doi.org/10.2807/1560-7917.ES.2018.23.6.17-00672>.
- 404 [16] Carretto E, Brovarone F, Russello G, Nardini P, El-Bouseary MM, Aboklaish AF, et al. Clinical  
405 validation of SensiTest colistin, a broth microdilution-based method to evaluate colistin MICs. *J Clin*  
406 *Microbiol* 2018;56. <https://doi.org/10.1128/JCM.01523-17>.
- 407 [17] Nordmann P, Jayol AAAA, Poirel L. Rapid Detection of Polymyxin Resistance in Enterobacteriaceae.  
408 *Emerg Infect Dis* 2016;22:1038–43. <https://doi.org/10.3201/eid2206.151840>.
- 409 [18] Mitton B, Kingsburgh C, Kock MM, Mbelle NM, Strydom K. Evaluation of an In-House Colistin NP  
410 Test for Use in Resource-Limited Settings. *J Clin Microbiol* 2019;57.  
411 <https://doi.org/10.1128/JCM.00501-19>.
- 412 [19] Poirel L, Larpin Y, Dobias J, Stephan R, Decousser J-W, Madec J-Y, et al. Rapid Polymyxin NP test for  
413 the detection of polymyxin resistance mediated by the mcr-1/mcr-2 genes. *Diagn Microbiol Infect Dis*  
414 2017;90:7–10. <https://doi.org/10.1016/j.diagmicrobio.2017.09.012>.
- 415 [20] Jayol AAA, Kieffer N, Poirel L, Guerin F, Guneser D, Cattoir V, et al. Evaluation of the Rapid  
416 Polymyxin NP test and its industrial version for the detection of polymyxin-resistant Enterobacteriaceae.  
417 *Diagn Microbiol Infect Dis* 2018;92:90–4. <https://doi.org/10.1016/j.diagmicrobio.2018.05.006>.
- 418 [21] Nordmann P, Assouvie L, Prod'Hom G, Poirel L, Greub G. Screening of plasmid-mediated MCR-1  
419 colistin-resistance from bacteremia. *Eur J Clin Microbiol Infect Dis* 2016;35:1891–2.  
420 <https://doi.org/10.1007/s10096-016-2739-0>.
- 421 [22] Abdul Momin MHF, Bean DC, Hendriksen RS, Haenni M, Phee LM, Wareham DW. CHROMagar  
422 COL-APSE: a selective bacterial culture medium for the isolation and differentiation of colistin-resistant  
423 Gram-negative pathogens. *J Med Microbiol* 2017;66:1554–61. <https://doi.org/10.1099/jmm.0.000602>.




- 424 [23] Ali S, Hussain W, Ahmed F, Afzal RK, Mirza I, Khurshid U. Chromagar™ Col-Apse for Detection of  
425 Colistin Resistance in Clinical Isolates of Multidrug Resistant Gram Negative Bacilli. J Coll Physicians  
426 Surg Pak 2022;32:177–80. <https://doi.org/10.29271/JCPSP.2022.02.177>.
- 427 [24] Germ J, Seme K, Cerar T, Krizan Hergouth V, Pirs M. Evaluation of two rapid phenotypical tests-Alifax  
428 rapid AST colistin test and Rapid Polymyxin NP test-for detection of colistin resistance in  
429 Enterobacterales. Eur J Clin Microbiol Infect Dis 2021;40:1749–53. <https://doi.org/10.1007/S10096-021-04182-W>.
- 430




431  
432 **Figure 1. Appearance of different bacterial species on the CHROMAgar-colAPSE chromogenic media. (A)** Bacterial  
433 growth on CHROMAgar Col-APSE showing different colony colours. **(B)** Swarming by *P. mirabilis* on CHROMAgar Col-  
434 APSE

435  
436 **Table S1.** Demographics, species, complete antibiotic resistance results data, and minimum inhibitory concentrations (MICs)  
437 of the isolates used in this study.



A



B

